Insider buying last 90 days
No open-market insider purchases were filed for QDEL in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every QDEL insider filing, plotted on the chart in Gekko.Open QDEL in Gekko
NASDAQ: QDEL
QuidelOrtho (QDEL) Stock Analysis & Forecast
Oct 12 close
$13.25−0.17 (−1.3%)
Gekko Brief
AI summaryOct 12 closeQuidelOrtho's stock drew attention this week after it amended its credit agreement to reset financial covenants through 2029, a move that accompanied a 12.72% jump on October 5, alongside a reported 2.8% increase in second-quarter 2026 revenue and a GAAP net loss of $92.9 million. Separately, the company named Sanjeev Sharma as Vice President of Investor Relations, effective September 28, bringing over 20 years of experience from Teva Pharmaceuticals and Genpact. A law firm, Halper Sadeh LLC, also disclosed an investigation into whether QuidelOrtho officers and directors breached fiduciary duties to shareholders.
QDEL closed at $13.25, down 1.3%, sitting just above its 50-day average of $13.13 but well below its 200-day average of $17.49. Shares range between a 52-week low of $9.92 and a high of $35.58, with a one-month return of 12.5% against three-month and six-month declines of -25% and -17.6%. The GekkoIndex reading of 47.9 places the stock in the Neutral zone, down from a five-day change of -10.1. Price sits 3.9% below Gekko Fair Value of $13.79.
QuidelOrtho next reports earnings on 4 November 2026, 23 days away and after the close, which falls inside a typical 20-trading-day holding window; its last report showed an EPS beat of $0.13 versus a -$0.05 estimate but a -29.8% reaction. No insider, Congress, or unusual options activity appears in the respective 90-day and 30-day windows. Seasonality over the past 5 years shows a -4.6% average return across the next 20 trading days, with gains in only 1 of those years, a pattern worth noting alongside the pending earnings date.
Written by AI from the Oct 12, 2026 close and checked automatically against the figures on this page.
QuidelOrtho price vs fair value
Close $13.25200-day averageGekko Fair Value $13.79
QuidelOrtho quick facts
- Market cap
- $903.5M
- P/E ratio
- —
- Forward P/E
- 9.6
- EPS, TTM
- −$15.39
- Revenue, TTM
- $2.67B
- Profit margin
- -39.2%
- Dividend yield
- —
- Beta
- 0.78
- Volume
- 2.64M avg 2.02M
- 1-year return
- −52.8%
- Typical daily move
- ±5.9%
- Typical 20-day move
- ±8.8%
- 50-day average
- $13.13
- 200-day average
- $17.49
- Next earnings
- Nov 4 after close
- Shares outstanding
- 68.58M
QuidelOrtho swing-trade checklist
QuidelOrtho scores 0 supportive, 3 mixed and 2 headwinds across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
0 supportive3 mixed2 headwinds
- Trendmixed
Averages disagree
Close $13.25 sits between the 50-day ($13.13) and 200-day ($17.49) averages, or the averages disagree.
See the chart - GekkoIndexmixed
47.9, Neutral
Reading 47.9 is in the Neutral zone.
See the GekkoIndex - Fair valuemixed
3.9% below
Price is within 5% of Gekko Fair Value (3.9% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings riskheadwind
Reports in 23 days
Reports on Nov 4, 2026, 23 days away — inside a typical 20-trading-day hold.
See earnings - Seasonalityheadwind
−4.6% on average
From this point in the calendar, the next 20 trading days averaged −4.6% over 5 years, rising in 1 of them.
See seasonality
A description of current data, not a recommendation. How this page works
QuidelOrtho stock chart and price history
QuidelOrtho closed at $13.25 on Oct 12, 2026, −52.8% over the past year, inside a 52-week range of $9.92 to $35.58.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- +12.5%
- 3 months
- −25.0%
- 6 months
- −17.6%
- 1 year
- −52.8%
The full QDEL chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open QDEL in Gekko
Follow QuidelOrtho through every session
Put QDEL on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track QDEL in GekkoFree for 7 days. No credit card required.
About QuidelOrtho
QuidelOrtho makes diagnostic tests and the instruments that run them, covering many different needs in patient testing. Its Labs business supplies chemistry and immunoassay equipment that reads bodily fluids and proteins, helping clinicians assess health, manage patients and watch how diseases progress. A separate Transfusion Medicine business checks blood and plasma for compatibility and infection risk, supporting safe transfusions. The company is also known for its Point-of-Care tests, which give fast answers in clinical settings, and for a Molecular Diagnostics line built around thermocyclers, analyzers and amplification tools used in PCR-based testing.
These four units, Labs, Transfusion Medicine, Point-of-Care and Molecular Diagnostics, form the structure of the company. Sales happen directly and through outside distributors, reaching hospitals, clinics, laboratories, universities, pharmacies, urgent care centers, retail health clinics, wellness screening sites, and blood and donor banks, as well as individual buyers of over-the-counter tests.
QuidelOrtho traces back to 1979 and runs its headquarters out of San Diego, California, with a presence that reaches North America, Europe, the Middle East, Africa and China. The stock trades on the NASDAQ under the ticker QDEL.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Medical specialties
- Website
- quidelortho.com
QuidelOrtho GekkoIndex: the smart money zone
QuidelOrtho’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 47.9, in the Neutral zone, down 10.1 points over five sessions.
47.9Neutral
Down 10.1 points over five sessions.
Reading for Oct 12, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 90 | −1.2% | −0.1% | ||
| Accumulation | 289 | −0.4% | −4.9% | ||
| Neutral (current zone) | 290 | −0.9% | −3.2% | ||
| Distribution | 12 | −3.4% | −12.0% | ||
| Selling | 1 | Too few readings yet | |||
Average QDEL share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +1.1% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
See every daily GekkoIndex reading plotted over the QDEL price, zone by zone.Track QDEL in Gekko
Is QuidelOrtho stock overvalued? Gekko Fair Value
QuidelOrtho trades 3.9% below Gekko Fair Value of $13.79, so the shares are about fair value on Gekko’s estimate.
Gekko’s own estimate of what QuidelOrtho shares are worth, recalculated every trading day.
$13.79
Gekko Fair Value, Oct 10, 2026
3.9% below fair value · About fair value
At the end of Aug 2026 the price was 4.3% below the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open QDEL in Gekko
QuidelOrtho insider and Congress trading
No open-market insider purchases were filed for QuidelOrtho, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in QDEL were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for QDEL, plotted on the chart in Gekko.Open QDEL in Gekko
Buybacks
QuidelOrtho has been buying back its own shares.
- Bought back, quarter ended Dec 29, 2024
- $900K
- As a share of market cap
- 0.10%
From company filings.
Hedge funds and billionaires quarter ended Jun 30
0of the funds Gekko tracks hold QDEL.
0added0opened0trimmed1sold out
Which funds are on each side, name by name.Unlock in Gekko
QuidelOrtho earnings: next date and track record
QuidelOrtho reports on Nov 4, 2026, after the close (23 days away), and beat the EPS estimate in 5 of its last 8 reports.
Next earnings report
Nov 4, 2026
Expected after the close, 23 days away
- EPS estimate
- $0.20
- Revenue estimate
- $628.1M
5 of 8reports beat the EPS estimate
±16.9%average move across the report
3 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Aug 6, 2026 AI summary
- What they said
- QDEL Q2 2026 total revenue grew 2% (6% excluding China), with Labs ex-China up 9%, immunohematology ex-China up 5%, and Triage up 9%. Adjusted EBITDA rose 21% to $129M with margin expanding 310bps to 20%. China revenue declined 23% due to IVD pricing guideline uncertainty. The company is commercializing its Neulixa point-of-care molecular platform following the April Lex acquisition.
- Guidance
- Management expects Neulixa customer placements and test utilization to gain momentum entering the respiratory season, targeting a growing installed base by the 2027-2028 season. No specific revenue or EPS targets were provided in this excerpt.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 6, 2026 | $0.13 est −$0.05 | $630.9M est $618.7M | −29.8% |
| May 5, 2026 | −$0.04 est $0.36 | $619.8M est $665.2M | −11.8% |
| Feb 11, 2026 | $0.46 est $0.51 | $723.6M est $700.7M | −18.7% |
| Nov 5, 2025 | $0.80 est $0.51 | $699.9M est $669.3M | −21.6% |
| Aug 5, 2025 | $0.12 est $0.56 | $615.1M est $676.5M | −2.8% |
| May 7, 2025 | $0.74 est $0.58 | $692.8M est $691.9M | +40.6% |
| Feb 12, 2025 | $0.63 est $0.55 | $707.8M est $718.2M | +0.4% |
| Nov 7, 2024 | $0.85 est $0.31 | $727.1M est $698.0M | +9.5% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
QuidelOrtho stock forecast and analyst price targets
Analysts’ average 12-month price target for QuidelOrtho is $14.67, +10.7% from the last close, from 2 firms rating the stock in the last 90 days.
$14.67consensus 12-month target, +10.7% from the last close
Each firm’s latest rating in the last 90 days: 2 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 24 | Craig-Hallum | — | — |
| Aug 24 | J.P. Morgan | $12 | −9.4% |
−3.2%average 20-day move after past Neutral readings
−4.6%average move over the next 20 trading days in the last 5 years
±5.9%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
QuidelOrtho seasonality: the next 20 trading days
Over the next 20 trading days from Oct 10, QuidelOrtho averaged −4.6% across the last 5 years, rising in 1 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +0.5% | 2 of 5 |
| Next 10 trading days | +2.6% | 2 of 5 |
| Next 15 trading days | +2.0% | 3 of 5 |
| Next 20 trading days | −4.6% | 1 of 5 |
| Next 30 trading days | +2.2% | 2 of 5 |
For scale, QDEL’s typical 20-trading-day move in either direction is about 8.8%.
QuidelOrtho market cap and key statistics
QuidelOrtho’s market cap is $903.5M and revenue of $2.67B over the last twelve months.
Valuation
- Market cap
- $903.5M
- Forward P/E
- 9.6
- EPS, TTM
- −$15.39
- Gekko Fair Value
- $13.79
Trading
- Volume
- 2.64M
- Avg volume, 20 days
- 2.02M
- 52-week high
- $35.58
- 52-week low
- $9.92
- Shares outstanding
- 68.58M
Financials
- Revenue, TTM
- $2.67B
- Profit margin
- -39.2%
- Return on equity
- -45.9%
- Quarterly earnings growth, YoY
- −77.1%
Risk and income
- Beta
- 0.78
- Typical daily move
- ±5.9%
- Typical 20-day move
- ±8.8%
QuidelOrtho stock news this week
Coverage of QuidelOrtho this week reads positive: 6 positive, 1 neutral and 3 negative headlines.
- Law firm probes QuidelOrtho officers for possib...Pluang, Oct 8
- Did QuidelOrtho Corporation Insiders Breach their Fiduciary Duties to Shareholders?PR Newswire, Oct 8
- QuidelOrtho Names Sanjeev Sharma Vice President of Investor Relationscitybiz, Oct 7
- QuidelOrtho appoints Sanjeev Sharma as VP of investor relations By Investing.comInvesting.com, Oct 7
- QuidelOrtho names Sanjeev Sharma as new VP of Investor Relations to boost investor engagement.Pluang, Oct 7
- QuidelOrtho Appoints Sanjeev Sharma as Vice President of Investor RelationsPR Newswire, Oct 7
QuidelOrtho peers
QuidelOrtho’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| TMOThermo Fisher Scientific | Neutral | 18.2% above |
| ABTAbbott Laboratories | Neutral | 14.7% below |
| DHRDanaher | Neutral | 4.5% above |
| ISRGIntuitive Surgical | Neutral | 18.8% above |
| MDTMedtronic | Neutral | 22.9% below |
| SYKStryker | Accumulation | 12.6% below |
A peer links to its own page where one exists.
QuidelOrtho stock FAQ
What is QuidelOrtho’s market cap?
QuidelOrtho’s market cap is $903.5M at the Oct 12, 2026 close of $13.25, with 68.58M shares outstanding.
What is the QuidelOrtho stock forecast?
The consensus analyst 12-month price target for QuidelOrtho is $14.67, +10.7% from the last close. Of the 2 firms that rated the stock in the last 90 days, 1 rate it a buy, 0 a hold and 1 a sell. Gekko doesn’t publish price predictions of its own.
Is QuidelOrtho stock overvalued or undervalued?
On Gekko’s estimate QuidelOrtho is about fair value: the Oct 12, 2026 close of $13.25 is 3.9% below Gekko Fair Value of $13.79. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does QuidelOrtho report earnings next?
QuidelOrtho is expected to report on Nov 4, 2026, after the market closes (23 days away). Analysts expect earnings of $0.20 per share on revenue of $628.1M. QuidelOrtho beat the earnings estimate in 5 of its last 8 reports, moving 16.9% on average across the report.
What is QuidelOrtho’s 52-week high and low?
QuidelOrtho’s 52-week high is $35.58 and its 52-week low is $9.92; it closed at $13.25 on Oct 12, 2026, −52.8% over the past year. Over the last five years the shares peaked at $180.06 on Dec 21, 2021.
Is QuidelOrtho stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 0 of the 5 items with data read as supportive, 3 as mixed (trend, gekkoindex and fair value) and 2 as headwinds (earnings risk and seasonality). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See QuidelOrtho the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,408 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.